A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

Part of paid clinical trials in Los Angeles, California.

Sponsor
Vor Biopharma
Study ID
NCT06456580
Phase
PHASE3
Status
Recruiting

Conditions

  • Generalized Myasthenia Gravis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Telitacicept — BIOLOGICAL
    Subcutaneous injection
  • Placebo — DRUG
    Subcutaneous injection

Study Details

The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of generalized myasthenia gravis.

Key Dates

Start date
Jul 17, 2024
Status verified
May 2026
Primary completion
May 31, 2027
Completion
Jan 31, 2029

Study Design

Enrollment
180 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Telitacicept
    Telitacicept
  • Placebo Comparator: Placebo
    Placebo

Primary Outcome Measure

Change from baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) score at Week 24 [ Time Frame: Week 24 ]

Central Contacts

Locations (20)

Find similar trials in Los Angeles, CA

Related Studies